To analyze population-level data for resectable gallbladder carcinoma (GBC) according to the eighth edition of the American Joint Committee on Cancer staging system.
Methods
We queried the Surveillance, Epidemiology, and End Results database to identify all patients aged 18 years or older with T1-3 M0 GBC diagnosed between 2004 and 2015. Multivariate cox hazard regression analysis was used to identify prognostic factors of cancer-specific survival (CSS).
Results
Of the 1601 eligible patients, 1310 (81.8%) underwent cholecystectomy only and 291 (18.2%) underwent an en bloc resection. Overall, 219 (13.7%) patients were in stage I, 400 (25%) were in stage II, 260 (16.2%) were in stage IIIA, 653 (40.8%) were in stage IIIB, and 69 (4.3%) were in stage IVB. The 5-year survival rates for patients were 82.7% for stage I, 73.4% for stage II, 31.9% for stage IIIA, 24.1% for stage IIIB, and 10% for stage IVB. Multivariate cox analysis indicated that predictors of decreased CSS included age at diagnosis >65 years, tumor size >3.2 cm, adenocarcinoma, increasing tumor spread, and lymph node involvement. Besides, chemotherapy and radiation were predictors of increased CSS.
Conclusions
Older age, increasing tumor size, adenocarcinoma, and advanced tumor/node stage were associated with a poorer prognosis after resection for GBC. Furthermore, patients with resectable GBC can benefit from adjuvant therapy.
Lazcano-PonceECMiquelJFMuñozN, et al.Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349-364.
2.
HundalRShafferEA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99-109.
3.
SiegelRLMillerKDFuchsHE, et al.Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33.
4.
DuffyACapanuMAbou-AlfaGK, et al.Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol. 2008;98(7):485-489.
5.
D'HondtMLapointeRBenamiraZ, et al.Carcinoma of the gallbladder: patterns of presentation, prognostic factors and survival rate. An 11-year single centre experience. Eur J Surg Oncol. 2013;39(6):548-553.
6.
HawkinsWGDeMatteoRPJarnaginWRBen-PoratLBlumgartLHFongY. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11(3):310-315.
7.
RegimbeauJMFuksDBachellierP, et al.Prognostic value of jaundice in patients with gallbladder cancer by the AFC-GBC-2009 study group. Eur J Surg Oncol. 2011;37(6):505-512.
8.
LimHSeoDWParkDH, et al.Prognostic factors in patients with gallbladder cancer after surgical resection: analysis of 279 operated patients. J Clin Gastroenterol. 2013;47(5):443-448.
9.
AminMBEdgeSGreeneF, et al.AJCC Cancer Staging Manual. 8th ed.New York: Springer; 2017.
10.
SungYNSongMLeeJH, et al.Validation of the 8th edition of the American Joint Committee on Cancer staging system for gallbladder cancer and implications for the follow-up of patients without node dissection. Cancer Res Treat. 2020;52(2):455-468.
11.
RoaIIbacacheGMuñozSde AretxabalaX. Gallbladder cancer in Chile: pathologic characteristics of survival and prognostic factors: analysis of 1,366 cases. Am J Clin Pathol. 2014;141(5):675-682.
12.
ShenHXSongHWXuXJ, et al.Clinical epidemiological survey of gallbladder carcinoma in North Western China, 2009-2013: 2379 cases in 17 centers. Chronic Dis Transl Med. 2017;3(1):60-66.
13.
LauCSMZywotAMahendrarajKChamberlainRS. Gallbladder carcinoma in the United States: a population based clinical outcomes study involving 22,343 patients from the surveillance, epidemiology, and end result database (1973-2013). HPB Surg. 2017;2017:1532835.
14.
AlexanderSLemmensVEHoutermanSNollenLRoumenRSlooterGD. Gallbladder cancer, a vanishing disease?Cancer Causes Control. 2012;23(10):1705-1709.
15.
ShindohJde AretxabalaXAloiaTA, et al.Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Ann Surg. 2015;261(4):733-739.
16.
LeeHChoiDWParkJY, et al.Surgical strategy for T2 gallbladder cancer according to tumor location. Ann Surg Oncol. 2015;22(8):2779-2786.
17.
LeeWJeongCYJangJY, et al.Do hepatic-sided tumors require more extensive resection than peritoneal-sided tumors in patients with T2 gallbladder cancer? Results of a retrospective multicenter study. Surgery. 2017;162(3):515-524.
18.
WangLDongPZhangYYangMChenYTianBL. Prognostic validation of the updated 8th edition Tumor-Node-Metastasis classification by the Union for International Cancer Control: survival analyses of 307 patients with surgically treated gallbladder carcinoma. Oncol Lett. 2018;16(4):4427-4433.
19.
ChoJKLeeWJangJY, et al.Validation of the oncologic effect of hepatic resection for T2 gallbladder cancer: a retrospective study. World J Surg Oncol. 2019;17(1):8.
20.
KimWJLimTWParkPJChoiSBKimWB. Clinicopathological differences in T2 gallbladder cancer according to tumor location. Cancer Control. 2020;27(1):1073274820915514.
21.
LeeSEChoiYSKimYH, et al.Prognostic significance of tumor location in T2 gallbladder cancer: a Korea Tumor Registry System Biliary Pancreas (KOTUS-BP) database analysis. J Clin Med. 2020;9(10):3268.
22.
JungWJangJYKangMJ, et al.Effects of surgical methods and tumor location on survival and recurrence patterns after curative resection in patients with T2 gallbladder cancer. Gut Liver. 2016;10(1):140-146.
23.
LiuGJLiXHChenYXSunHDZhaoGMHuSY. Radical lymph node dissection and assessment: impact on gallbladder cancer prognosis. World J Gastroenterol. 2013;19(31):5150-5158.
24.
LeighNLSolomonDFeingoldD, et al.Staging gallbladder cancer with lymphadenectomy: the practical application of new AHPBA and AJCC guidelines. HPB (Oxford). 2019;21(11):1563-1569.
25.
SaharaKTsilimigrasDIMaithelSK, et al.Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: an analysis of the US extrahepatic biliary malignancy consortium. J Surg Oncol. 2020;121(3):503-510.
26.
MaegawaFBAshouriYHamidiMHsuCHRiallTS. Gallbladder Cancer surgery in the United States: lymphadenectomy trends and impact on survival. J Surg Res. 2021;258:54-63.
27.
YadavSTellaSHKommalapatiA, et al.A novel clinically based staging system for gallbladder cancer. J Natl Compr Canc Netw. 2020;18(2):151-159.
28.
ZhangWHongHJChenYL. Establishment of a gallbladder cancer-specific survival model to predict prognosis in non-metastatic gallbladder cancer patients after surgical resection. Dig Dis Sci. 2018;63(9):2251-2258.
29.
ZhangYZhouTHanS, et al.Development and external validation of a nomogram for predicting the effect of tumor size on cancer-specific survival of resected gallbladder cancer: a population-based study. Int J Clin Oncol. 2021;26(6):1120-1129.
30.
FosterJMHoshiHGibbsJF, et al.Gallbladder cancer: defining the indications for primary radical resection and radical re-resection. Ann Surg Oncol. 2007;14(2):833-840.
31.
de Savornin LohmanEde BitterTVerhoevenR, et al.Trends in treatment and survival of gallbladder cancer in the Netherlands; identifying gaps and opportunities from a Nation-Wide Cohort. Cancers. 2020;12(4):918.
32.
JaruvongvanichVYangJDPeeraphatditTRobertsLR. The incidence rates and survival of gallbladder cancer in the USA. Eur J Cancer Prev. 2019;28(1):1-9.
33.
HensonDEAlbores-SaavedraJCorleD. Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates. Cancer. 1992;70(6):1493-1497.
34.
AloiaTAJárufeNJavleM, et al.Gallbladder cancer: expert consensus statement. HPB (Oxford). 2015;17(8):681-690.
35.
KurosakiIHatakeyamaKMinagawaMSatoD. Portal vein resection in surgery for cancer of biliary tract and pancreas: special reference to the relationship between the surgical outcome and site of primary tumor. J Gastrointest Surg. 2008;12(5):907-918.
36.
D’AngelicaMDalalKMDeMatteoRPFongYBlumgartLHJarnaginWR. Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol. 2009;16(4):806-816.
37.
JarnaginWRRuoLLittleSA, et al.Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98(8):1689-1700.
38.
DixonEVollmerCMJrSahajpalA, et al.An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg. 2005;241(3):385-394.
39.
ChanSYPoonRTLoCMNgKKFanST. Management of carcinoma of the gallbladder: a single-institution experience in 16 years. J Surg Oncol. 2008;97(2):156-164.
40.
MargonisGAGaniFBuettnerS, et al.Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. HPB (Oxford). 2016;18(11):872-878.
41.
NCCN (National Comprehensive Cancer Network). NCCN Clinical Practice Guidelines in Oncology-Hepatobiliary Cancers. Version 1[DB/OL], 2021. http://www.nccn.org.
42.
ValleJWBorbathIKhanSAHuguetFGruenbergerTArnoldD. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28-v37.
43.
PrimroseJNFoxRPPalmerDH, et al.Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663-673.
44.
ShroffRTKennedyEBBachiniM, et al.Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12):1015-1027.
